In a Mexican model of chronic hepatitis C, triple therapy (peginterferon, ribavirin and thymosin alpha‑1) had lower cost and higher utility than peginterferon plus ribavirin, peginterferon alone and no treatment.
In plain wordsIn a cost model for hepatitis C, a three-drug regimen that includes thymosin alpha‑1 cost less and gave more benefit than the other options.
- Peptide
- Thymosin alpha-1
- Outcome
- MixedCost and utility of triple therapy versus other options
- Study
n: not reported in source
- Comparator
- Peginterferon plus ribavirin, peginterferon alone, no treatment
- Outcome group
- Cost-effectiveness · Infection
Source sentences
Triple therapy (peginterferon plus ribavirin plus thymosin alpha-1) was dominant with lower cost and higher utility in relationship with peginterferon + ribavirin option, peginterferon alone and no-treatment option.
2 context sentences(design, population, supporting numbers)
The objective of the study was to determine the most cost-effective treatment against HCV among the following: peginterferon, peginterferon plus ribavirin, peginterferon plus ribavirin plus thymosin, and no treatment.
We carried out cost-effectiveness analysis using the institutional perspective, including a 45-year time frame and a 3% discount rate for costs and effectiveness.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.